AZD7442 for COVID-19 (PROVENT Trial)

"The primary objective of this study, which will be measured over a 457 day period, is to assess the incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness. Additionally, this trial will also collect data on secondary outcomes including The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies, The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP, and Serum AZD7442 concentrations"

"According to the latest information found on clinicaltrials.gov, this study is not currently recruiting patients for participation. The trial was first posted on November 21st, 2020 and was last updated on January 20th, 2022. Although this specific trial isn't searching for candidates, there are 1,131 other studies that are actively recruiting right now."

"Currently, this clinical trial is being conducted at 52 sites. A few locations include Noblesville, Evansville and Lauderdale Lakes but there are many more. Minimizing travel burden is an important factor to consider when selecting a location, so please choose the site closest to you."

"Unfortunately, this particular clinical trial is no longer actively recruiting patients. The listing was created on November 21st 2020 and last updated January 20th 2022. If you are still interested in participating in studies related to covid-19, there are 1126 active listings enrolling participants and 5 trials for AZD7442 that have open recruitment."

"This ongoing clinical trial is looking for 5197 patients who currently have covid-19 and are between the ages of 18 and 120. In order to be eligible, patients must also meet the following criteria: they can benefit from passive immunization with antibodies, they are medically stable, they have a negative result from point of care SARS-CoV-2 serology testing at screening, contraceptive used by women of child bearing potential, condom used by men, able to understand and comply with study requirements/procedures based on the assessment of the investigator The participant has been randomized, dosed, and is ongoing in the PROV"

"There is both preclinical and clinical data supporting the safety of AZD7442, so it received a score of 3."

"The age limit for participants in this study is 120 years old, with a minimum age of 18."

"There are five clinical studies currently underway for AZD7442, four of which have reached Phase 3. Trials for this medication are being conducted at 598 different facilities, with a notable concentration in Anniston, Alabama."